GM608 / Genervon - LARVOL DELTA

GAP-PD-Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (clinicaltrials.gov) - P2a; N=6; Completed; Sponsor: Genervon Biopharmaceuticals, LLC; Recruiting ➔ Completed; Trial primary completion date: Dec 2013 ➔ Jul 2014

Trial completion • Trial primary completion date • Biosimilar • Parkinson's Disease